---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-25-000026"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:43:14.266406+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q1 revenue $27.1M, net loss narrows to $22.6M; cash runway into 2H-2027

## Summary
- Revenue of $27.1M (vs. $10.0M in Q1 2024); net loss of $22.6M improved from $31.7M.
- Cash resources $321.6M; combined with anticipated milestones expected to fund operations into 2H-2027.
- Partner Jazz received EMA positive opinion for zanidatamab in HER2+ BTC; final decision pending.
- Recognized $14.0M GSK milestone (paid Apr 2025) and $3.1M Daiichi Sankyo milestone; additional milestones remain.
- Appointed Dr. Sabeen Mekan as SVP Clinical Development; six preclinical posters presented at AACR.

## SEC filing metadata
- accession: 0001937653-25-000026
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/0001937653-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/zyme-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-25-000026
- JSON: https://secwatch.observer/filing/0001937653-25-000026.json
- Plain text: https://secwatch.observer/filing/0001937653-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.